European Equities Traded in US as ADRs Rise in Thursday Trading

MT Newswires Live06-11 23:09

European equities traded in the US as American depositary receipts rose late Thursday morning with the S&P Europe Select ADR Index climbing 1.7% to 1,874.97.

From continental Europe, the gainers were led by biopharmaceutical company argenx (ARGX) and semiconductor company Sequans Communications (SQNS), which rose 2.7% and 2.6%, respectively. They were followed by biotech firm BioNTech (BNTX) and telecommunications company Nokia (NOK), which were up 2.5% and 1.6%, respectively.

The decliners from continental Europe were led by software firm SAP (SAP) and internet ad firm Criteo (CRTO), which dropped 4.1% and 0.9%, respectively. They were followed by biotech firm Evaxion (EVAX) and consumer goods company Unilever (UL), which were off 0.4% and 0.1%, respectively.

The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which climbed 8.8% and 4%, respectively. They were followed by lender HSBC (HSBC) and biotech firm Autolus Therapeutics (AUTL), which advanced 2.8% and 2.7%, respectively.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and software company Endava (DAVA), which fell 4.6% and 1.1%, respectively. They were followed by biopharmaceutical companies Mereo BioPharma Group (MREO) and NuCana (NCNA), which lost 0.9% and 0.8%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment